Buys | $0 | 0 | 0 |
Sells | $919,142 | 10 | 100 |
Ferstler Sherri Lee | Senior VP, Sales | 0 | $0 | 1 | $20,263 | $-20,263 |
BURKE WILLIAM W | director | 0 | $0 | 1 | $35,150 | $-35,150 |
Birkemeyer Elaine M. | Chief Financial Officer | 0 | $0 | 3 | $127,107 | $-127,107 |
Burns Kristie | Sr. VP Mktg & Clinical Affairs | 0 | $0 | 3 | $175,625 | $-175,625 |
REUVERS DANIEL L. | director | 0 | $0 | 2 | $560,997 | $-560,997 |
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the …
Over the last 12 months, insiders at Tactile Systems Technology, Inc. have bought $0 and sold $919,142 worth of Tactile Systems Technology, Inc. stock.
On average, over the past 5 years, insiders at Tactile Systems Technology, Inc. have bought $44,835 and sold $1.13M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,900 shares for transaction amount of $44,835 was made by BURKE WILLIAM W () on 2022‑08‑04.
2025-02-25 | Sale | REUVERS DANIEL L. | director | 28,338 0.1132% | $14.18 | $401,850 | -3.63% | |
2025-02-25 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 2,066 0.0084% | $14.51 | $29,980 | -3.63% | |
2025-02-25 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 6,468 0.0262% | $14.40 | $93,160 | -3.63% | |
2025-02-24 | Sale | REUVERS DANIEL L. | director | 10,938 0.0448% | $14.55 | $159,147 | -5.44% | |
2025-02-24 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 3,778 0.0156% | $14.70 | $55,538 | -5.44% | |
2025-02-24 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 4,830 0.0199% | $14.65 | $70,753 | -5.44% | |
2024-08-12 | Sale | Ferstler Sherri Lee | Senior VP, Sales | 1,550 0.0065% | $13.07 | $20,263 | +13.72% | |
2024-05-16 | Sale | Birkemeyer Elaine M. | Chief Financial Officer | 3,041 0.0129% | $13.68 | $41,590 | +3.84% | |
2024-05-08 | Sale | BURKE WILLIAM W | director | 2,500 0.0107% | $14.06 | $35,150 | +2.09% | |
2024-05-06 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 815 0.0035% | $14.37 | $11,713 | -0.35% | |
2024-02-29 | Sale | REUVERS DANIEL L. | President and CEO | 1,396 0.0059% | $15.25 | $21,289 | -5.70% | |
2024-02-29 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 243 0.001% | $15.25 | $3,706 | -5.70% | |
2024-02-27 | Sale | REUVERS DANIEL L. | President and CEO | 4,689 0.0196% | $15.60 | $73,148 | -9.96% | |
2024-02-27 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 1,091 0.0045% | $15.58 | $17,001 | -9.96% | |
2024-02-26 | Sale | REUVERS DANIEL L. | President and CEO | 6,239 0.0269% | $15.81 | $98,645 | -7.22% | |
2024-02-26 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 2,015 0.0087% | $15.90 | $32,049 | -7.22% | |
2024-02-23 | Sale | REUVERS DANIEL L. | President and CEO | 5,378 0.0215% | $14.85 | $79,853 | -9.22% | |
2024-02-23 | Sale | Burns Kristie | Sr. VP Mktg & Clinical Affairs | 2,249 0.009% | $14.80 | $33,278 | -9.22% | |
2023-08-07 | Sale | REUVERS DANIEL L. | President and CEO | 1,062 0.0046% | $20.53 | $21,808 | -31.97% | |
2023-05-12 | Sale | BURKE WILLIAM W | director | 4,400 0.021% | $21.86 | $96,184 | -29.68% |
BURKE WILLIAM W | director | 25273 0.1072% | $332,592.68 | 1 | 14 | +42.19% |
SODERBERG PETER H | director | 236450 1.0025% | $3.11M | 1 | 0 | +38.26% |
Moen Brent | Chief Financial Officer | 48760 0.2067% | $641,681.60 | 1 | 9 | <0.0001% |
NIGON RICHARD | director | 16785 0.0712% | $220,890.60 | 3 | 5 | +21.69% |
Pegus Cheryl | director | 2184 0.0093% | $28,741.44 | 1 | 0 | +77.98% |
Increased Positions | 76 | +47.2% | 2M | +7.55% |
Decreased Positions | 69 | -42.86% | 3M | -11.59% |
New Positions | 37 | New | 834,040 | New |
Sold Out Positions | 28 | Sold Out | 1M | Sold Out |
Total Postitions | 168 | +4.35% | 21M | -4.03% |
Blackrock, Inc. | $33,972.00 | 9.9% | 2.38M | -17,668 | -0.74% | 2024-12-31 |
Morgan Stanley | $32,645.00 | 9.52% | 2.28M | -26,421 | -1.14% | 2024-12-31 |
Cadian Capital Management, Lp | $24,857.00 | 7.25% | 1.74M | -195,102 | -10.09% | 2024-12-31 |
Paradigm Capital Management Inc/Ny | $23,754.00 | 6.93% | 1.66M | -2,500 | -0.15% | 2024-12-31 |
Vanguard Group Inc | $21,202.00 | 6.18% | 1.48M | +4,509 | +0.3% | 2024-12-31 |
Dimensional Fund Advisors Lp | $12,883.00 | 3.76% | 901,551 | +67,934 | +8.15% | 2024-12-31 |
Nuveen Asset Management, Llc | $9,689.00 | 2.83% | 678,026 | -207,186 | -23.41% | 2024-12-31 |
Wasatch Advisors Lp | $9,036.00 | 2.64% | 632,317 | -94,877 | -13.05% | 2024-12-31 |
Deutsche Bank Ag | $8,811.00 | 2.57% | 616,612 | -272,258 | -30.63% | 2024-12-31 |
Geode Capital Management, Llc | $7,990.00 | 2.33% | 559,162 | +495 | +0.09% | 2024-12-31 |